To report or not to report: Exploring healthy volunteers' rationales for disclosing adverse events in Phase I drug trials
{{output}}
Background: Phase I trials test the safety and tolerability of investigational drugs and often use healthy volunteers as research participants. Adverse events (AEs) are collected in part through participants' self-reports of any ... ...
